KLDO - Kaleido concludes enrollment in KB109 study in COVID-19

Kaleido Biosciences ([[KLDO]] +4.0%) has completed enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy ((MMT)) candidate KB109 for the treatment of mild-to-moderate COVID-19.The multi-center, non-IND clinical study is designed to evaluate the effects of KB109 plus supportive self-care ((SSC)) compared to SSC alone for outpatients who are positive for SARS-COV-2 and have symptoms.Study endpoints include safety and tolerability, biomarkers of the inflammatory response, and time to resolution of symptoms.The KB109 development program involves two controlled, non-IND clinical studies including one study of 350 patients evaluating symptom resolution and one study of ~50 patients evaluating effects on microbiome composition and biomarkers of inflammatory response.

For further details see:

Kaleido concludes enrollment in KB109 study in COVID-19